Publications by authors named "M Van Hemelrijck"
Background: Oesophago-gastric cancer surgery negatively affects quality of life with a high postoperative symptom burden. Several conditions that may be diagnosed and treated after surgery are recognised. However, consensus regarding their definition and management is lacking.
View Article and Find Full Text PDFBackground: When faced with treatment options, patients are asked to participate in decision-making. We sought to determine which treatment aspects matter most for individuals treated for muscle invasive bladder cancer (MIBC), with an aim to improve understanding of patient preferences and what trade-offs patients are willing to accept. Our study consisted of a discrete choice experiment (DCE): a type of questionnaire used to elicit preferences in the absence of real-world choice.
View Article and Find Full Text PDFArticle Synopsis
- The study examines the relationship between oral bacteria and infective endocarditis (IE), highlighting the shift in antibiotic prophylaxis (AP) guidelines in 2007/2008 that limited AP to high-risk patients only.
- Researchers analyzed data from University Hospital Zurich (2000-2022) to determine if oral streptococcal IE cases rose in moderate-risk patients following these guideline changes.
- Results showed that moderate-risk patients had a significantly higher risk of oral streptococcal IE after the guidelines were updated, suggesting that expanding AP to include certain moderate-risk groups, particularly those with congenital valve anomalies, may be necessary.*
Article Synopsis
- Stage IIIA-N2 non-small cell lung cancer (NSCLC) has low survival rates and lacks a standardized treatment, making patient management difficult.
- This study analyzed 142 patients to assess overall survival (OS) and disease-free survival (DFS), finding the median OS to be 31 months, with no significant differences between treatment methods.
- The results emphasize the need for personalized treatment plans and collaborative decision-making among healthcare professionals, with future research aimed at new therapies and multi-centre trials.